Payment overview · 2025
General Payments
$278.06
22 reported records · 5 companies
Healthcare provider profile · identity verified
Amanda Kay Williams, DO
Allopathic & Osteopathic Physicians|Family Medicine|Geriatric Medicine · LONDON, OH · NPI 1104147669
Verified facts
What the public records show
CMS Open Payments records show Amanda Kay Williams, DO received $278.06 in general payments during 2025 across 22 reported records.
ABBVIE INC. accounted for 64.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $179.45 | 64.5% | 15 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $36.08 | 13.0% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $28.43 | 10.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.09 | 6.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.01 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $278.06 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $107.16 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $85.44 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $61.89 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $39.39 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $36.08 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $28.43 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.09 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $10.40 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $5.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 557 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 427 | 92 |
| Furosemide | Furosemide | 355 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 331 | 73 |
| Potassium Chloride | Potassium Chloride | 269 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 263 | 53 |
| Losartan Potassium | Losartan Potassium | 237 | 55 |
| Lisinopril | Lisinopril | 220 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 219 | 55 |
| Gabapentin | Gabapentin | 197 | 38 |
| Omeprazole | Omeprazole | 189 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 173 | 43 |
| Trazodone Hcl | Trazodone Hcl | 173 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 38 |
| Metformin Hcl | Metformin Hcl | 148 | 35 |
| Simvastatin | Simvastatin | 136 | 31 |
| Alprazolam | Alprazolam | 122 | 22 |
| Tramadol Hcl | Tramadol Hcl | 117 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 23 |
| Alendronate Sodium | Alendronate Sodium | 106 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 29 |
| Sertraline Hcl | Sertraline Hcl | 100 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 98 | 25 |
| Allopurinol | Allopurinol | 96 | 19 |
| Carvedilol | Carvedilol | 90 | 15 |
| Buspirone Hcl | Buspirone Hcl | 89 | 17 |
| Myrbetriq | Mirabegron | 86 | suppressed |
| Bupropion Xl | Bupropion Hcl | 81 | 20 |
| Memantine Hcl | Memantine Hcl | 80 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 17 |
| Atenolol | Atenolol | 78 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 21 |
| Montelukast Sodium | Montelukast Sodium | 62 | 14 |
| Donepezil Hcl | Donepezil Hcl | 59 | 12 |
| Mirtazapine | Mirtazapine | 59 | 17 |
| Eliquis | Apixaban | 58 | 12 |
| Ozempic | Semaglutide | 57 | 14 |
| Nifedipine Er | Nifedipine | 56 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 52 | suppressed |
| Spironolactone | Spironolactone | 51 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | suppressed |
| Famotidine | Famotidine | 48 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 46 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 17 |
| Glipizide Er | Glipizide | 44 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 17 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 41 | suppressed |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 39 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 39 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 11 |
| Cephalexin | Cephalexin | 37 | 22 |
| Lorazepam | Lorazepam | 37 | suppressed |
| Glimepiride | Glimepiride | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Gemtesa | Vibegron | 29 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 29 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Prednisone | Prednisone | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 22 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Dofetilide | Dofetilide | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $278.06 · 22 records | ABBVIE INC. | CREON, INGREZZA, Korlym, LINZESS, QULIPTA, SYNTHROID, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Synthroid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error